SEC Form 4 · accession 0001209191-18-046313
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederic Pla
Officer — Chief Bus & Prod Dev Officer
Period of report
Aug 9, 2018
Accepted (ET)
Aug 10, 2018 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 9, 2018 | M | 1,500 | $27.00 | A | 41,038 | D | |
| Common StockF2,F3,F4,F1 | Aug 9, 2018 | S | 800 | $55.5237 | D | 40,238 | D | |
| Common StockF2,F3,F5,F1 | Aug 9, 2018 | S | 700 | $56.4143 | D | 39,538 | D | |
| Common StockF2,F3,F4,F1 | Aug 9, 2018 | S | 2,100 | $55.4831 | D | 37,438 | D | |
| Common StockF2,F3,F6,F1 | Aug 9, 2018 | S | 1,900 | $56.4221 | D | 35,538 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) HoldingF7 | $27.00 | Aug 9, 2018 | M | 1,500 | D | — | Feb 16, 2026 | Common Stock | 1,500 | 60,200 | D |
Explanation of responses
- F1Includes an aggregate of 18,734 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 7, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $55.09 to $55.96.
- F5Represents weighted average sale price. Actual sale prices ranged from $56.12 to $56.91.
- F6Represents weighted average sale price. Actual sale prices ranged from $56.12 to $56.94.
- F7The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.